ReCode Therapeutics secured up to $15 million in a corporate round led by the Cystic Fibrosis Foundation to develop a gene editing therapy for cystic fibrosis.
PRIVATENov 18, 2024
Amount Raised
$15 Million
Round Type
Corporate Round
Menlo ParkBiotechnologyHealthcareHealth Care
Investors
Cystic Fibrosis Foundation
Description
The Cystic Fibrosis Foundation has agreed to invest up to $15 million in ReCode Therapeutics to support their collaboration with Intellia Therapeutics. The funding will aid in the development of a gene editing therapy intended for lung cells of individuals suffering from cystic fibrosis.
Who to call at ReCode Therapeutics, and when
A new round usually means ReCode Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day ReCode Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at ReCode Therapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
ReCode Therapeutics
Location
Menlo Park, California, United States
About
ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ReCode Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Menlo ParkBiotechnologyHealthcareHealth Care